Humana (NYSE:HUM) Updates FY24 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of at least $16.00 for the period, compared to the consensus estimate of $16.15.

Humana Price Performance

HUM opened at $293.09 on Tuesday. Humana has a twelve month low of $213.31 and a twelve month high of $502.73. The company has a fifty day simple moving average of $275.33 and a 200 day simple moving average of $329.24. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a market cap of $35.29 billion, a price-to-earnings ratio of 25.96, a PEG ratio of 2.34 and a beta of 0.53.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Equities research analysts expect that Humana will post 15.86 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.21%. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Wall Street Analyst Weigh In

HUM has been the topic of several recent analyst reports. Leerink Partnrs downgraded Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target for the company in a report on Tuesday, October 8th. Oppenheimer decreased their price objective on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd. JPMorgan Chase & Co. raised their price target on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Finally, Piper Sandler lowered shares of Humana from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. Twenty research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.